Aethlon Medical Announces Debt-To-Equity Conversion Results.Business Editors/Health & Medical Writers LA JOLLA La Jolla (lə hoi`yə), on the Pacific Ocean, S Calif., an uninc. district within the confines of San Diego; founded 1869. The beautiful ocean beaches, in particular La Jolla shores and Black's Beach, and sea-washed caves attract visitors and , Calif.--(BW HealthWire)--June 4, 2002 Aethlon Medical Aethlon Medical Inc. is a publicly traded company based in San Diego, California. It currently trades under the symbol AEMD (OTC BB). James A. Joyce is the Chairman and CEO, while Dr. Harold Handley is the current President of the organization. Inc., (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AEMD AEMD Automotive Electric Motor Drive (US Department of Energy program) ) a company developing therapeutic devices for the treatment of HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome , Hepatitis-C and other infectious diseases, announced today the results of a debt-to-equity conversion program that expired on May 31, 2002. Under the conversion program, $1,265,479 of outstanding debt was converted into Aethlon Medical common shares and stock purchase warrants. The conversion price was $1.25 per share, and included the issuance of one stock purchase warrant for every two shares that were acquired through the conversion. Each issued warrant has an exercise price of $2.00 per share and expires three years from the date of issuance. As a result, 1,012,384 shares of common stock and 506,192 warrants were issued under the program. The adjusted number of shares outstanding as of June 1, 2002 is 5,386,722. About Aethlon Medical Aethlon Medical Inc. develops therapeutic devices that treat HIV/AIDS, Hepatitis-C and other infectious diseases. In pre-clinical testing, Aethlon's lead product, AEMD-45, removes 55 percent of HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. from human blood in three hours and in excess of 85 percent in 12 hours. The AEMD-45 therapeutic device is developed from an expansive platform technology known as the Hemopurifier(TM), which employs a proprietary method of modifying artificial kidneys (hemodialysis cartridges) to mimic the immune system's response to clear infectious virus from circulation before healthy cells can be infected. AEMD-45 is designed to fill the urgent need for new treatments that are effective in reducing viral load viral load n. The concentration of a virus, such as HIV, in the blood. viral load, n a measure of the number of virus particles present in the bloodstream, expressed as copies per milliliter. , decrease the likelihood of treatment resistance and treat without the side effects Side effects Effects of a proposed project on other parts of the firm. of current AIDS drugs. For more information, visit the company's Web site at www.AethlonMedical.com. Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to raise capital when needed, the company's ability to complete the development of its planned products, the ability of the company to obtain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals permitting the sale of its products, the company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the company's Securities and Exchange Commission filings. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion